|
Market Closed -
London S.E.
11:35:20 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 1,868.50 GBX | +0.73% |
|
+5.51% | +2.41% |
| 06:12pm | GSK's ibsago approved in the US for treatment of chronic hepatitis B | AN |
| 10-20 | US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment | RE |
ETFs positioned on GSK plc
| Name | YTD change | Weight | AuM | |
|---|---|---|---|---|
 | +10.61% | - | 24,432 M€ | |
| +16.35% | - | 750 M€ | |
| -.--% | - | 22 M€ | |
| +13.62% | - | 44 M€ | |
| +5.61% | - | 49 M€ | |
| +0.71% | - | 51 M€ | |
| +10.68% | - | 66 M€ | |
| +9.47% | - | 75 M€ | |
| +8.50% | - | 6,576 M€ | |
| +7.90% | - | 274 M€ | |
| +12.72% | - | 122 M€ | |
| +5.89% | - | 1,193 M€ | |
| +13.06% | - | 1,674 M€ | |
| +7.10% | 9.81% | 28 M€ | |
| +4.38% | 8.02% | 9 M€ | |
| +9.47% | 7.14% | 987 M€ | |
| -.--% | 7.14% | 987 M€ | |
| +8.95% | 6.59% | 12 M€ | |
| +4.36% | 5.94% | 1,024 M€ | |
| +12.06% | 5.9% | 38 M€ | |
| +7.32% | 5.9% | 90 M€ | |
| +5.84% | 5.86% | 56 M€ | |
| -1.30% | 5.75% | 12 M€ | |
| +2.21% | 5.75% | 820 M€ | |
| +4.41% | 5.14% | 58 M€ | |
| +7.06% | 5.09% | 11 M€ | |
| +4.67% | 5.09% | 667 M€ | |
| +11.74% | 5.02% | 19 M€ | |
| +4.29% | 4.94% | 9 M€ | |
| +6.69% | 4.92% | 1,018 M€ | |
| 0.00% | 4.18% | 8 M€ | |
| +62.58% | 4.1% | 215 M€ | |
| +12.86% | 4.03% | 1,807 M€ | |
| +10.33% | 3.8% | 2,529 M€ | |
| +9.21% | 3.62% | 50 M€ | |
| +7.63% | 3.57% | 106 M€ | |
| +5.76% | 3.57% | 19 M€ | |
| +7.95% | 3.57% | 147 M€ | |
| +11.23% | 3.57% | 1,166 M€ | |
| +8.83% | 3.48% | 935 M€ | |
| +7.50% | 3.36% | 1,190 M€ | |
| -.--% | 3.36% | 1,190 M€ | |
| +12.01% | 3.33% | 114 M€ | |
| +10.87% | 3.33% | 265 M€ | |
| +10.70% | 3.31% | 1,211 M€ |
Employees
66,841
Sector
Pharmaceuticals
Calendar
- Stock Market
- Stocks
- GSK Stock
- ETFs GSK plc
Select your edition
All financial news and data tailored to specific country editions
